How many more breast cancer predisposition genes are there? by Easton, Douglas F
14
Commentary
How many more breast cancer predisposition genes are there?
Douglas F Easton
Cancer Research Campaign (CRC), Cambridge, UK
Received: 16 July 1999
Accepted: 22 July 1999
Published: 23 August 1999
© Current Science Ltd
Important note about how to cite this article
This article is also available online in the Breast Cancer Research
website. To avoid confusion, please ensure that only the online version
of the article is cited in any reference, as follows:
Easton DF: How many more breast cancer predisposition genes are
there? [commentary]. http://breast-cancer-research.com/vol1no1/
23aug99/editorial/1
http://breast-cancer-research.com/vol1no1/23aug99/editorial/1
Next year marks the 10th anniversary of the mapping of
the breast–ovarian cancer susceptibility gene BRCA1 to
chromosome 17 [1], and the identification of the TP53
gene as the cause of the Li-Fraumeni syndrome [2]. As a
result of these discoveries, and the subsequent discovery
of other breast cancer susceptibility genes, notably BRCA2
[3], inherited susceptibility has risen from relative obscu-
rity to have a central role in breast cancer research. Under-
standing the biological mechanisms that underlie the
susceptibility genes has become a major research activity,
and of course mutation testing is now a major part of clini-
cal genetics practice, with the prospects for improved
prevention and treatment of the disease in women at high
risk. Thus, it is natural to ask whether there are any more
genes to find, what their characteristics might be and how
we might go about finding them.
Of the five genes that are, beyond any reasonable doubt,
breast cancer predisposition genes, the BRCA1 and BRCA2
genes are the most important numerically (Table 1). Muta-
tions in these genes, which cause high risks of breast and
ovarian cancer, account for almost all the multiple case
breast–ovarian cancer families, and probably around 2% of
breast cancer cases overall [4,5]. Germline mutations in the
TP53 gene predispose to a spectrum of cancers known as
the Li-Fraumeni syndrome, including childhood sarcomas
and brain tumours, as well as early-onset breast cancer [2];
and germline mutations in the PTEN gene are responsible
for Cowdens syndrome, of which breast cancer is a major
feature [6]. Mutations in a fifth gene, the androgen receptor
gene, are known to predispose to breast cancer in men [7].
In addition to the five genes mentioned above, there is
good, but not conclusive, evidence for two others. Female
relatives of ataxia–telangiectasia patients have been shown
in a number of studies [8,9] to be at increased risk of
breast cancer (and perhaps of some other cancers), sug-
gesting that heterozygous carriers of mutations in the
ataxia–telangiectasia gene, ATM, are at increased risk of
breast cancer. The results from different studies are rea-
Table1
Known or suspected breast cancer genes
Cumulative risk by age† Contribution to
Gene Location Allele frequency* 50 years (%) 70 years (%) Breast cancer (%) Familial risk (%)
BRCA1 17q 0.0005–0.002 50 70‡ 1–2 8
BRCA2 13q 0.0005–0.002 30 70‡ 1–2 8
TP53 17p 0.0001 ~50 <1 <1
PTEN 10q <0.0001 ~30? <<1 <1
ATM 11q 0.003 6 18 2 2
HRAS1 11q 0.06 3 10 9 4
*Plausible estimate for large outbred populations. †In the absence of
other causes of death; these figures are intended as a guide only.
‡Some studies suggest lower risks for BRCA1 and BRCA2.http://breast-cancer-research.com/vol1no1/23aug99/editorial/1
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sonably consistent, and are confirmed by direct observa-
tion of haplotype sharing in breast cancer cases in relatives
of ataxia–telangiectasia patients [10]. The residual doubt
lies in the fact that, to date, no studies have demonstrated
this association in breast cancer case–control studies [11].
There is also evidence that carriers of a certain class of rare
alleles of the HRAS1 minisatellite locus are at increased
risk of breast (and other) cancers, the relative risk being
approximately twofold [12]. The doubts that surround this
association are that the typing of this locus is technically
difficult, and has not been attempted on a sufficient
number of large case–control studies to be really
convincing, and that the mechanistic interpretation of this
association remains obscure.
So what evidence is there for the existence of any other
susceptibility genes? The most direct way to address this
question is to ask whether the known genes can explain
the observed familial aggregation of breast cancer. Like
most other common cancers, breast cancer exhibits famil-
ial aggregation, with the disease being about twice as
common in the mothers, sisters and daughters of cases as
it is in the general population [13–17]. This ‘familial rela-
tive risk’ rises to around fivefold for cases aged below
40years [18]. In principle this familial aggregation may be
due to either genes or to environmental factors shared
within families, but evidence from monozygotic twins of
cases (who have approximately twice the risk of first-
degree relatives) suggest that genetic factors are mainly
responsible [19]. Familial relative risk is a useful measure
of overall amount of variation in inherited susceptibility
to the disease, and any familial risk ‘unexplained’ by the
known genes provides evidence for other genes [20].
A number of studies have now tested for BRCA1 and
BRCA2 mutations in population-based series of breast
cancer cases, and these allow one to estimate directly the
contribution of these genes to familial aggregation, provid-
ing there are also good data on family history and an esti-
mate of mutation sensitivity. In the largest study
published to date, Peto et al [5] found a total of 30 muta-
tions in 617 breast cancer patients diagnosed below age
46years. When the family histories of these 30 mutation
carriers were examined, it was found that only five of their
mothers or sisters had had breast cancer, compared with
64 in the relatives of the 587 noncarriers. After allowing for
the number of breast cancers that would be expected at
population rates, and assuming a mutation sensitivity of
64% [4], this would equate to approximately 16% of the
observed familial risk being due to BRCA1 and BRCA2.
This observation fits well with linkage results derived by
the Breast Cancer Linkage Consortium [4]. Over 80% of
families with six or more cases of breast cancer were found
to be linked to either BRCA1 or BRCA2 (even in the
absence of ovarian cancer in relatives), but the proportion
dropped to 40% in families with four or five cases.
Mutations in the TP53 and PTEN genes are very rare and
are probably responsible for less than 1% of familial breast
cancer. The importance of ATM can only be assessed
indirectly. On the basis of the best available estimates of
allele frequency (about 0.002) and relative risk (about
fourfold),  ATM would be expected to cause a familial rela-
tive risk, on its own, of about 1.02, or about 2% of the
observed familial risk, although this could possibly be as
high as 6 or 7%. On the basis of risks given by Krontiris et
al [12], HRAS1 would be expected to explain a further 4%
of the familial risk. Taking all of these effects together, it
appears that the known susceptibility genes can only
account for around 20–25% of the familial risk.
What types of gene might underlie the remaining 75–80%
of familial breast cancer? In principle, it ought to be possi-
ble to address this using segregation analysis, based on
families without BRCA1 or BRCA2 mutations. Previous
segregation analyses (eg [21]) were quite successful at
identifying a major gene component responsible for a
subset of cases, consistent with the effects of BRCA1 and
BRCA2. Unfortunately, however, segregation analysis
tends to be weak at discrimating models unless there is a
clear major gene component. Antoniou et al (personal com-
munication), using mutation and family history data from a
large population-based series of breast cancer patients
from East Anglia, UK, have shown that a variety of both
single gene and polygenic models can give an adequate fit
once BRCA1 and BRCA2 are allowed for.
Nevertheless we can draw some general conclusions about
the likely characteristics of other susceptibility genes:
(1) There are several genes involved. The genomic
linkage searches that mapped BRCA1 and BRCA2
would have had adequate power to map a third gene,
had it been responsible for most or all of the remaining
families, but in fact no further loci have emerged.
(Linkage to the oestrogen receptor on chromosome 6p
[22] and to chromosome 8p [23,24] have been sug-
gested in some families, but to date these have not
been confirmed in other studies.)
(2) There are no further genes with penetrances compara-
ble to those of BRCA1 or BRCA2, or at least if there are,
the predisposing mutations in these genes must be
very rare. In the Breast Cancer Linkage Consortium
analysis of Ford et al [4], there were 78 families with six
or more patients breast cancer younger than 60 years
old. Of these, all but nine either had a BRCA1 or
BRCA2 mutation, or had clear linkage evidence in
favour of one of these loci, and only one (reported by
Seitz et al [24]) actually had strong evidence against
linkage to either locus (LODs<–1).
(3) Some of the genes show age-specific effects. The
trend in familial relative risk with age, which is consis-
tently observed in epidemiological studies, cannot be
accounted for by BRCA1 or BRCA2 alone, and there-Breast Cancer Research    Vol 1 No 1 Easton
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fore other genes must also confer relative risks that
decrease with age. (For this reason, early onset breast
cancers remain more informative for both linkage and
association studies than late-onset disease.)
(4) A rare recessive gene model is unlikely, because the
large population studies give very similar sibling and
parent–offspring risks [13–17]. A model involving a
gene or genes with common recessive alleles would,
however, be quite possible.
(5) The genes do not (on the whole) confer substantial
risks of any other cancer. The relatives of breast cancer
patients have not been consistently shown to suffer
significant risks of any other cancer except ovarian
cancer, and this association can be explained by
BRCA1 and  BRCA2 [25].
(6) There is some suggestion that lobular breast cancer and
lobular carcinoma in situ show bigger familial risks than
other histological types of breast cancer [26,27]. This
effect does not appear to be due to BRCA1 or BRCA2 so
it does suggest that other genes may predispose prefer-
entially to lobular carcinoma [28]. Non-BRCA1/2 famil-
ial breast cancer also tends to be of lower grade than
breast cancer in BRCA1 or BRCA2 carriers, and perhaps
than ‘sporadic’ breast cancer as well [28].
Although the above observations are useful for guiding
collections of cases and families, the range of plausible
genetic models for the remaining genes is still very wide.
At one extreme, there is still room for several genes
causing quite substantial relative risks, say 10- to 15-fold.
A number of mutations with a combined frequency of 2%,
each causing a 10-fold risk of the disease, could ade-
quately explain the familial risks and the many multiple
case families not due to BRCA1 or BRCA2. Such a model
would be quite plausible given a moderate degree of
selection against carriers (for example, if homozygotes
were nonviable). Under this model one would expect a
substantial degree of allelic heterogeneity, with popula-
tion-specific mutations, as for BRCA1 or BRCA2. In fact,
these genes (which one might expect to call BRCA3,
BRCA4,  BRCA5, etc) would be qualitatively similar to
BRCA1 and BRCA2, but conferring somewhat lower
absolute risks (although responsible for a higher fraction of
cases overall). One would speculate that they are likely to
have inactivating mutations and act as tumour suppressor
genes. Such genes ought to be mappable by genetic
linkage, providing that the genetic heterogeneity is not
too severe. For example, if there were four such genes
each responsible for one-quarter of the families, a series of
around 400 families with three affected sisters should be
sufficient to map them, given a sufficiently dense marker
map. This would be a substantial undertaking (at least
four-fold larger than the current linkage searches) but
would be achievable with international collaboration.
Families collected from isolated populations with small
numbers of founders, such as French Canadians or
Afrikaaners, could be a major advantage here. Such popu-
lations are likely to have less genetic heterogeneity, and it
may be possible to link families to a common founder,
increasing their informativeness.
At the other extreme are ‘low-risk’ polymorphisms,
causing relative risks of less than fivefold. To be of much
interest, these polymorphisms need to be quite frequent
in the population (hence, we would not normally describe
them as ‘mutations’). This in turn implies that homozy-
gotes must be viable and that there can be little or no
selection against heterozygotes. These polymorphisms are
most likely to be single nucleotide polymorphisms leading
to amino acid substitutions, although inactivating muta-
tions in nonessential genes (for example, genes coding for
certain metabolizing enzymes) and polymorphisms in reg-
ulatory sequences may also be important. The human
genome contains vast numbers of such polymorphisms;
recent surveys suggest around 200000–400000 with fre-
quencies of a few percent [29,30], and the majority of
genes appear to have at least one polymorphism, so it is
reasonable to postulate that a few of these single
nucleotide polymorphisms do influence breast cancer risk.
Finding common low-risk polymorphisms related to breast
cancer would be almost impossible by linkage analysis,
and attention has turned to direct testing in case–control
association studies, which are able to detect genes with
much lower relative risks. An association study based on
1000 breast cancer cases and 1000 control individuals
should be able to detect polymorphisms that cause rela-
tive risks as low as 1.5, with allele frequencies of 15% or
more. There is room for around 30 such polymorphisms,
given the overall familial relative risk of the disease. In
this sense, association studies are about one order of mag-
nitude more powerful than linkage studies, which are
probably limited to three or four more genes. The total
number of polymorphisms related to breast cancer risk
could be much larger of course, but polymorphisms with
very small effects will not be detectable.
A large number of such association studies have already
been conducted, concentrating on polymorphisms in ‘can-
didate genes’ that are thought to be relevant to the devel-
opment of breast cancer. A number of positive associations
have been found in individual studies, but few have been
replicated. In a recent meta-analysis, Dunning et al [31]
analysed 17 polymorphisms that had been studied for
association with breast cancer by at least two groups. Only
one of them, the Ile105 polymorphism in GSTP1, was sig-
nificant when data were combined across all studies, and
this was only marginally so. The lack of success of this
approach so far may be partly blamed on the small sample
size often employed, but it does suggest that the impor-
tant genes have yet to be examined. Many of the genes
tested so far have been involved in steroid hormonemetabolism, and it may be that some other types of
genetic variation, for example in DNA repair fidelity, or
metabolism of some specific dietary factors, are more
important. The major drawback of association studies is
that, unlike in linkage studies, it is necessary to guess the
gene in advance, and type the causative polymorphism or
at least a very tightly linked polymorphism in strong dise-
quilibrium. One is therefore limited by one’s existing
knowledge of mechanisms. Fortunately, this is set to
change over the next few years, as the catalogue of
common single nucleotide polymorphisms becomes more
complete, and the technology for typing them becomes
more rapid and less expensive; ultimately, it may be possi-
ble to test all common coding single nucleotide polymor-
phisms in this way. Even this exhaustive search could
miss some important susceptibility genes, for example
low-risk genes with substantial allelic heterogeneity (as in
the case of HRAS1). Overall, the prospects for finding
more breast cancer genes over the next few years are good,
but a complete enumeration of all important genes may
prove more difficult.
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